Abeona Therapeutics’ (ABEO) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research note issued to investors on Wednesday, Marketbeat Ratings reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the company. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $18.00 target price on shares of Abeona Therapeutics in a report on Tuesday, October 29th.

Abeona Therapeutics Price Performance

Shares of NASDAQ:ABEO opened at $5.78 on Wednesday. Abeona Therapeutics has a 12 month low of $3.05 and a 12 month high of $9.01. The stock has a market cap of $251.26 million, a price-to-earnings ratio of -2.15 and a beta of 1.43. The stock’s 50 day moving average price is $5.65 and its 200 day moving average price is $5.81. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Twinbeech Capital LP bought a new position in shares of Abeona Therapeutics in the fourth quarter valued at $58,000. Squarepoint Ops LLC bought a new position in shares of Abeona Therapeutics in the fourth quarter valued at $67,000. Jane Street Group LLC bought a new position in shares of Abeona Therapeutics in the third quarter valued at $84,000. Oxford Asset Management LLP bought a new position in shares of Abeona Therapeutics in the fourth quarter valued at $118,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Abeona Therapeutics in the third quarter valued at $151,000. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.